A Study to Identify and Characterize LAL-D Patients in High-risk Populations
NCT02345421 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 640
Last updated 2016-05-24
Summary
The objective of this study is to determine the frequency of Lysosomal Acid Lipase Deficiency (LAL D) by lysosomal acid lipase (LAL) enzyme activity assay in patients who are considered to be at risk.
Conditions
- Lysosomal Acid Lipase Deficiency
Sponsors & Collaborators
-
Alexion Pharmaceuticals, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 2 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-12-31
- Primary Completion
- 2015-09-30
- Completion
- 2015-10-31
Countries
- United States
Study Locations
More Related Trials
-
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
NCT01371825 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity
NCT00106912 ·Status: COMPLETED
-
Screening of Lysosomal Storage Disorders Diseases in Minority Groups
NCT03812042 ·Status: UNKNOWN
-
Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta
NCT01745185 ·Status: COMPLETED
-
Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease
NCT02800070 ·Status: COMPLETED ·Phase: PHASE1
-
Real World Evidence Study of Danish Fabry Patients
NCT06303466 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of Fabrazyme in Pediatric Patients With Fabry Disease
NCT00074958 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
NCT00081497 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
NCT07187440 ·Status: RECRUITING
-
Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)
NCT02104219 ·Status: COMPLETED
-
Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201
NCT04999059 ·Status: TERMINATED
-
Study of the Prevalence of Fabry Disease in French Dialysis Patients
NCT02843334 ·Status: UNKNOWN
-
Alpha-Galactosidase A Replacement Therapy for Fabry Disease
NCT00048906 ·Status: COMPLETED ·Phase: PHASE2
-
LGMD R1 Natural History Study
NCT05618080 ·Status: RECRUITING
-
Epidemiological Study of Fabry Disease Screening in Chronic Kidney Disease Patients
NCT05056636 ·Status: UNKNOWN
-
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
NCT05698901 ·Status: RECRUITING
-
Investigating Lysosomal Storage Diseases in Minority Groups
NCT02120235 ·Status: UNKNOWN
-
A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease
NCT00074984 ·Status: COMPLETED ·Phase: PHASE4
-
Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease
NCT02956954 ·Status: COMPLETED ·Phase: NA
-
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
NCT02116712 ·Status: COMPLETED ·Phase: PHASE1
-
Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients With Antiphospholipid Syndrome.
NCT03384485 ·Status: UNKNOWN ·Phase: NA
-
Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.
NCT01997489 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment
NCT07277361 ·Status: RECRUITING
-
GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study
NCT02525861 ·Status: COMPLETED ·Phase: PHASE3
-
Detection of Fabry Disease in Chronic Renal Failure Patients in Area Provence - Alpes - Côte d'Azur
NCT01374997 ·Status: COMPLETED ·Phase: NA